CLNN

Company Overview — What Does Clene Inc. Do?

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Clene Inc. (CLNN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert D. Etherington and employs approximately 100 people. With a market capitalization of $58M, CLNN is one of the notable companies in the Healthcare sector.

Clene Inc. (CLNN) Stock Rating — Reduce (April 2026)

As of April 2026, Clene Inc. receives a Reduce rating with a composite score of 28.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CLNN ranks #3,120 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Clene Inc. ranks #456 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLNN Stock Price and 52-Week Range

Clene Inc. (CLNN) currently trades at $6.00. The stock lost $0.34 (5.4%) in the most recent trading session. The 52-week high for CLNN is $13.50, which means the stock is currently trading -55.6% from its annual peak. The 52-week low is $2.28, putting the stock 163.1% above its annual trough. Recent trading volume was 35K shares, suggesting relatively thin trading activity.

Is CLNN Overvalued or Undervalued? — Valuation Analysis

Clene Inc. (CLNN) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 351.11x, compared to 1.66x for the average Healthcare stock.

At current multiples, Clene Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Clene Inc. Profitability — ROE, Margins, and Quality Score

Clene Inc. (CLNN) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -111.8% versus the sector average of -33.1%.

On a margin basis, Clene Inc. reports gross margins of 88.7%, compared to 71.5% for the sector. The operating margin is -18346.7% (sector: -66.1%). Net profit margin stands at -24024.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -83.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CLNN Debt, Balance Sheet, and Financial Health

Balance sheet data for CLNN is evaluated through our stability factor. The current ratio is 1.53x, suggesting adequate working capital coverage. Total debt on the balance sheet is $18M. Cash and equivalents stand at $8M.

CLNN has a beta of 1.03, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Clene Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Clene Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Clene Inc. reported revenue of $210,000 and earnings per share (EPS) of $-0.85. Net income for the quarter was $-25M. Gross margin was 88.7%. Operating income came in at $-23M.

In Q3 2025, Clene Inc. reported revenue of $15,000 and earnings per share (EPS) of $-0.85. Net income for the quarter was $-9M. Gross margin was 100.0%. Revenue grew -82.8% year-over-year compared to Q3 2024. Operating income came in at $-6M.

In Q2 2025, Clene Inc. reported revenue of $27,000 and earnings per share (EPS) of $-0.78. Net income for the quarter was $-7M. Gross margin was 100.0%. Revenue grew -70.3% year-over-year compared to Q2 2024. Operating income came in at $-6M.

In Q1 2025, Clene Inc. reported revenue of $81,000 and earnings per share (EPS) of $-0.09. Net income for the quarter was $-751,000. Gross margin was 75.3%. Revenue grew 11.0% year-over-year compared to Q1 2024. Operating income came in at $-4M.

Over the past 8 quarters, Clene Inc. has demonstrated a growth trajectory, with revenue expanding from $73,000 to $210,000. Investors analyzing CLNN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLNN Dividend Yield and Income Analysis

Clene Inc. (CLNN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CLNN Momentum and Technical Analysis Profile

Clene Inc. (CLNN) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

CLNN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Clene Inc. (CLNN) ranks #456 out of 838 stocks based on the Blank Capital composite score. This places CLNN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CLNN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLNN vs S&P 500 (SPY) comparison to assess how Clene Inc. stacks up against the broader market across all factor dimensions.

CLNN Next Earnings Date

No upcoming earnings date has been announced for Clene Inc. (CLNN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLNN? — Investment Thesis Summary

The quantitative profile for Clene Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. Momentum is weak at 39/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, Clene Inc. (CLNN) earns a Reduce rating with a composite score of 28.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLNN stock.

Related Resources for CLNN Investors

Explore more research and tools: CLNN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLNN head-to-head with peers: CLNN vs AZN, CLNN vs SLGL, CLNN vs VMD.